Media Articles Related to Istodax (Romidepsin)
New treatment option for subtype of aggressive lymphoma ALCL
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2015.05.12]
An international team of researchers, including Lukas Kenner from the Clinical Department of Pathology at MedUni Vienna, has discovered a specific combination of mutations and new gene fusions...
Fitness May Help Lower Odds for Non-Hodgkin's Lymphoma
Source: MedicineNet Non-Hodgkins Lymphomas Specialty [2015.05.04]
Title: Fitness May Help Lower Odds for Non-Hodgkin's Lymphoma
Category: Health News
Created: 5/1/2015 12:00:00 AM
Last Editorial Review: 5/4/2015 12:00:00 AM
Lifetime intense physical activity may lower risk for non-hodgkin lymphoma
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2015.05.01]
Performing vigorous physical activity over one's lifetime may lower risk for non-Hodgkin lymphoma (NHL).
Hodgkin lymphoma survivors have higher risk for cardiovascular diseases
Source: Lymphoma / Leukemia / Myeloma News From Medical News Today [2015.04.28]
Survivors of Hodgkin lymphoma appear to be at higher risk for cardiovascular diseases and both physicians and patients need to be aware of this increased risk, according to an article published...
Hodgkin's Lymphoma Survivors Face Higher Long-Term Heart Risks
Source: MedicineNet Hodgkins Disease Specialty [2015.04.28]
Title: Hodgkin's Lymphoma Survivors Face Higher Long-Term Heart Risks
Category: Health News
Created: 4/27/2015 12:00:00 AM
Last Editorial Review: 4/28/2015 12:00:00 AM
Published Studies Related to Istodax (Romidepsin)
Romidepsin for peripheral T-cell lymphoma. 
Peripheral T-cell lymphoma (PTCL) is comprised of a rare heterogeneous group of
diseases with diverse clinical presentations; however outcomes associated with
conventional chemotherapy are generally poor in the majority of patients. Newer
approaches, which include dose-intensification and agents with novel mechanisms
of action, are needed to improve outcomes in this group of patients...
Romidepsin: a novel histone deacetylase inhibitor for cancer. [2011.08]
Introduction: Romidepsin is a novel histone deacetylase (HDAC) inhibitor, with a recent approval for treatment of cutaneous T-cell lymphoma (CTCL).Future directions include expanded indications in T-cell lymphomas as well as novel combinations with other HDAC inhibitors and other therapeutic agents.
Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. [2011.08]
Romidepsin (Istodax), a selective inhibitor of histone deacetylases (HDACs), was approved for the treatment of cutaneous T-cell lymphoma in November 2009 by the US Food and Drug Administration. This unique natural product was discovered from cultures of Chromobacterium violaceum, a Gram-negative bacterium isolated from a Japanese soil sample...
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. [2011.06.02]
Romidepsin (depsipeptide or FK228) is a histone deacetylase inhibitor, one of a new class of agents active in T-cell lymphoma. A phase 2 trial was conducted in cutaneous (CTCL) and peripheral (PTCL) T-cell lymphoma... The histone deacetylase inhibitor romidepsin has single agent clinical activity associated with durable responses in patients with relapsed PTCL.
A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. [2011.05]
Romidepsin, a potent histone deacetylase inhibitor, has shown activity in preclinical glioma models. The primary objectives of this trial were to determine the pharmacokinetics of romidepsin in patients with recurrent glioma on enzyme-inducing antiepileptic drugs (EIAEDs) and to evaluate the antitumor efficacy of romidepsin in patients with recurrent glioblastoma who were not receiving EIAEDs...
Clinical Trials Related to Istodax (Romidepsin)
A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas [Recruiting]
This study is an open label, multicenter study with two phases:
- A dose escalation phase of Romidepsin administered IV at day 1 and 8 or at day 1
without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and
prednisone (CHOP)administered every 3 weeks for 8 cycles in patients with T-cell
- An expansion phase in order to assess the safety and the efficacy of the association of
the recommended dose of Romidepsin associated with CHOP in a population of patients
with T-cell lymphoma.
Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma [Recruiting]
- Cutaneous T-cell lymphoma (CTCL) is a rare, slow-growing form of skin cancer. The
cancer cells are found in red, scaly patches that may sometimes itch.
- Early-stage CTCL is usually treated with topical therapies, which may lose
effectiveness over time and have adverse effects, such as risk of secondary skin
cancers and difficulty of use.
- Romidepsin is an experimental drug that, given through a vein, has improved CTCL in
some patients with later stages of the disease.
- A topical ointment form of romidepsin may be helpful in treating early-stage CTCL.
- To determine the highest tolerated dose of topical romidepsin that can be given to
patients with early-stage CTCL.
- To evaluate the effectiveness of topical romidepsin in patients with early-stage CTCL.
- To determine how the body handles topical romidepsin.
- Patients 18 of age and older with early-stage CTCL.
- Study Part 1: Successive groups of 3 patients are treated with increasingly higher
concentrations of topical romidepsin until the highest tolerated dose is found.
- Study Part II: The highest tolerated dose, as determined in Part I, is applied to
larger areas of skin in another group of patients.
- All study participants apply the study medicine to their skin three times a day for 4
- During treatment, participants are monitored at weeks 2 and 4 with a history and
physical examination, blood tests, electrocardiogram, skin biopsies and photographs of
- After stopping treatment, participants return to the clinic at weeks 6 and 8 for blood
tests and to see how the study medication is affecting the body.
Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer [Recruiting]
A Rollover Study for Subjects Who Participated in Other Romidepsin Protocols [Recruiting]
This study is intended to provide access to Romidepsin for subjects who received Romidepsin
in other trials sponsored by Gloucester Pharmaceuticals or Celgene Corporation and for
subjects whom the investigator feels may benefit from continuing treatment with Romidepsin.
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer [Recruiting]
Reports of Suspected Istodax (Romidepsin) Side Effects
Decreased Appetite (6),
Pulmonary Oedema (5),
Infusion Site Extravasation (4),
Peripheral Sensory Neuropathy (4),
General Physical Health Deterioration (4),
Febrile Neutropenia (4), more >>